Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty

Severe asthma affects between 5% and 10% of patients with asthma worldwide and requires best standard therapies at maximal doses, but there is a subgroup of patients refractory to all treatments. We share a case report of a 53-year-old woman with a history of severe allergic asthma that progressivel...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzella, Francesco, Galeone, Carla, Lusuardi, Mirco, Simonazzi, Anna, Castagnetti, Claudia, Ruggiero, Patrizia, Facciolongo, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687776/
https://www.ncbi.nlm.nih.gov/pubmed/29184413
http://dx.doi.org/10.2147/TCRM.S149775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687776/
https://www.ncbi.nlm.nih.gov/pubmed/29184413
http://dx.doi.org/10.2147/TCRM.S149775

Ejemplares similares